Stockreport

CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

CohBar, Inc.  (CWBR) 
NASDAQ:AMEX Investor Relations: ir.cohbar.com
PDF MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (M [Read more]